BAG3 and pancreatic adenocarcinoma: Therapeutically, targeting extracellular BAG3 with monoclonal neutralizing antibodies in murine pancreatic adenocarcinoma models reduced fibrosis and macrophage infiltration, resulting in inhibited tumor progression (37, 45).